LAMEA Telmisartan Market By Indication (Hypertension and Cardiovascular Risk Reduction), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies), By Country, Growth Potential, Industry Analysis Report and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Telmisartan Market
Market Report Description
The Latin America, Middle East and Africa Telmisartan Market would witness market growth of 6.9% CAGR during the forecast period (2020-2026). Telmisartan is also known as Micardis. Similar to the ARBs, telmisartan is available across in different combination tablets. Telmisartan is equally as efficient as olmesartan in reducing blood pressure.
In addition to reducing blood pressure, telmisartan offers two other advantages: reducing blood sugar levels (by increasing insulin sensitivity) and decreasing cholesterol levels. The included blood sugar advantage makes telmisartan different from losartan & olmesartan. All these factors will support the growth of the telmisartan market during the forecast period.
The growth of the market would experience a boost due to the rising awareness about hypertension and its management by organizing global campaigns. For example, in May 2017, the Argentinian Society of Hypertension (SAHA) took participation in global campaigns like ‘May Measurement Month and World Hypertension Day’ with an aim to spread awareness among people about high blood pressure and its management.
The Hospital Pharmacies market dominated the Saudi Arabia Telmisartan Market by Distribution Channel in 2019, thereby, achieving a market value of $34.3 million by 2026. The Drug Stores and Retail Pharmacies market is estimated to grow at a CAGR of 7.7% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments Covered in the Report:
- Cardiovascular Risk Reduction
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free